CP-122,288 is a drug which acts as a potent and selective
agonist for the
5-HT1B,
5-HT1D and
5-HT1F serotonin receptor subtypes. It is a derivative of the
migraine medication
sumatriptan, but while CP-122,288 is 40,000 times more potent than sumatriptan as an inhibitor of neurogenic inflammation and plasma protein extravasation, it is only twice as potent as a constrictor of blood vessels. In human trials, CP-122,288 was not found to be effective as a treatment for migraine, but its selectivity for neurogenic anti-inflammatory action over vasoconstriction has made it useful for research into the underlying causes of migraine.
See also
*
5-MeO-MPMI
5-MeO-MPMI (also known as 5-Methoxy-''N''-methyl-(α,''N''-trimethylene)tryptamine) is a tryptamine derivative that is a psychedelic drug. It was first developed by the team led by JE Macor in 1992, and subsequently investigated by the team led b ...
*
CP-135807
CP-135807 is a drug which acts as a potent and selective agonist for the 5-HT1D serotonin receptor, and is used to study the function of this receptor subtype.
See also
* 4-HO-MPMI
* 5-MeO-MPMI
* Eletriptan
Eletriptan, sold under the brand ...
*
Eletriptan
Eletriptan, sold under the brand name Relpax and used in the form of eletriptan hydrobromide, is a second generation triptan medication intended for treatment of migraine headaches. It is used as an abortive medication, blocking a migraine att ...
References
5-HT1B agonists
5-HT1D agonists
5-HT1F agonists
Pyrrolidines
Tryptamines
Amines
{{nervous-system-drug-stub